OneSource Specialty Pharma Ltd Q1 FY27 Results Analysis: Revenue Surges 37%, PAT Turns Profitable

OneSource Specialty Pharma Ltd's Q1 FY27 numbers came in strong. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Consolidated revenue grew 37% YoY and PAT turned profitable, driven by strong standalone performance. However, subsidiary losses and a large contingent liability persist, tempering overall quality. The margin recovery is encouraging but cost structure shifts warrant monitoring.

Key Investment Insights

Key Positives

• Consolidated revenue grew 37.2% YoY to Rs.449.02 Cr from Rs.327.27 Cr.
• Consolidated PAT turned from loss of Rs.0.19 Cr to profit of Rs.25.00 Cr.
• Standalone PAT doubled to Rs.51.23 Cr, up 106.4% YoY.
• EBITDA grew 39.1% YoY to Rs.119.05 Cr, with margin expanding 504 bps QoQ to 26.51%.
• Revenue grew 4.9% sequentially from Q4 FY26.

Risk Factors

• Subsidiaries caused a persistent profit drag of Rs.26.23 Cr on consolidated PAT.
• Consumables cost surged to 22.02% of revenue from 11.35% a year ago, indicating a mix shift to higher-cost work.
• Finance costs rose 36.9% QoQ to Rs.30.81 Cr, likely reflecting debt drawn for capacity expansion.
• Contingent liability of USD 136.32 Mn from Prestige litigation remains an overhang.